Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients

Autor: Chen CC, Rane PB, Hines DM, Patel J, Harrison DJ, Wade RL

Publikováno v: Therapeutics and Clinical Risk Management, Vol Volume 14, Pp 2425-2435 (2018)

Chi-Chang Chen,1 Pallavi B Rane,2 Dionne M Hines,1 Jeetvan Patel,2 David J Harrison,2 Rolin L Wade1 1IQVIA, Plymouth Meeting, PA, USA; 2Amgen Inc., Thousand Oaks, CA, USA Background: This study evaluated the proportion of patients with atheroscleroti

Externí odkaz: https://doaj.org/article/9e5fcf5fcd2147419f6864f44ac37dac

Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context

Autor: Wu N, Bhurke S, Shah N, Harrison DJ

Publikováno v: ClinicoEconomics and Outcomes Research, Vol 2015, Iss default, Pp 257-266 (2015)

Ning Wu,1 Sharvari Bhurke,1 Neel Shah,2 David J Harrison2 1Health Economics and Epidemiology, Evidera, Lexington, MA, USA; 2Amgen Inc., Thousand Oaks, CA, USA Background: Several biologic medicines are available to treat rheumatoid arthritis (RA), an

Externí odkaz: https://doaj.org/article/5e9ea44143a44639a3a16d2324ccd7d9

Overcoming intratumoural heterogeneity for reproducible molecular risk stratification : a case study in advanced kidney cancer

Autor: Lubbock, ALR, Stewart, Grant, O'Mahony, FC, Laird, A, Mullen, P, O'Donnell, M, Powles, T, Harrison, DJ, Overton, IM

Publikováno v: Lubbock, A, Stewart, G, O'Mahony, F, Laird, A, Mullen, P, O'Donnell, M, Powles, T, Harrison, D J & Overton, I 2017, ' Overcoming Intratumoural Heterogeneity for Reproducible Molecular Risk Stratification: A Case Study in Advanced Kidney Cancer ', BMC Medicine . https://doi.org/10.1186/s12916-017-0874-9
Lubbock, A, Stewart, G, O'Mahony, F C, Laird, A, Mullen, P, O'Donnell, M, Powles, T, Harrison, D J & Overton, I 2017, ' Overcoming Intratumoural Heterogeneity for Reproducible Molecular Risk Stratification: A Case Study in Advanced Kidney Cancer ', BMC Medicine, vol. 15, 118 . https://doi.org/10.1186/s12916-017-0874-9
BMC Medicine, Vol 15, Iss 1, Pp 1-12 (2017)

BACKGROUND: Metastatic clear cell renal cell cancer (mccRCC) portends a poor prognosis and urgently requires better clinical tools for prognostication as well as for prediction of response to treatment. Considerable investment in molecular risk strat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d721e22c9ff22d2636a01ed185c0b54
https://hdl.handle.net/10023/11092

Genetic and epigenetic analyses of MBD3 in colon and lung cancer.

Autor: Zhu, Y¹, Harrison, DJ¹, Bader, SA¹ sbader@ed.ac.uk

Publikováno v: British Journal of Cancer. 5/17/2004, Vol. 90 Issue 10, p1972-1975. 4p.

Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications

Autor: Tiede, C, Tang, AA, Deacon, SE, Mandal, U, Nettleship, JE, Owen, RL, George, SE, Harrison, DJ, Owens, RJ, Tomlinson, DC, McPherson, MJ

We have designed a novel non-antibody scaffold protein, termed Adhiron, based on a phytocystatin consensus sequence. The Adhiron scaffold shows high thermal stability (Tm ca. 101°C), and is expressed well in Escherichia coli. We have determined the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::412d8f1ab871124cce996f6ae64987bf